A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. by Hann, Hie-Won et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medicine Faculty Papers Department of Medicine
4-2014
A long-term study of the effects of antiviral therapy
on survival of patients with HBV-associated
hepatocellular carcinoma (HCC) following local
tumor ablation.
Hie-Won Hann
Thomas Jefferson University, Hie-Won.Hann@jefferson.edu
Robert Coben
Thomas Jefferson University, robert.coben@jefferson.edu
Daniel Brown
Thomas Jefferson University, Daniel.Brown@jefferson.edu
Laurence Needleman
Thomas Jefferson University, laurence.needleman@jefferson.edu
Ernest Rosato
Thomas Jefferson University, Ernest.Rosato@jefferson.edu
See next page for additional authorsLet us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/medfp
Part of the Oncology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Recommended Citation
Hann, Hie-Won; Coben, Robert; Brown, Daniel; Needleman, Laurence; Rosato, Ernest; Min,
Albert; Hann, Richard; Park, Kyong Bin; Dunn, Stephen; and DiMarino, Anthony J., "A long-term
study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular
carcinoma (HCC) following local tumor ablation." (2014). Department of Medicine Faculty Papers.
Paper 170.
http://jdc.jefferson.edu/medfp/170
Authors
Hie-Won Hann, Robert Coben, Daniel Brown, Laurence Needleman, Ernest Rosato, Albert Min, Richard
Hann, Kyong Bin Park, Stephen Dunn, and Anthony J. DiMarino
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/medfp/170
ORIGINAL RESEARCH
A long-term study of the effects of antiviral therapy on
survival of patients with HBV-associated hepatocellular
carcinoma (HCC) following local tumor ablation
Hie-Won Hann1,2, Robert Coben2, Daniel Brown3, Laurence Needleman3, Ernest Rosato4,
Albert Min5, Richard S. Hann1, Kyong Bin Park6, Stephen Dunn7 & Anthony J. DiMarino2
1Liver Disease Prevention Center, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
2Division of Gastroenterology and Hepatology, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
3Department of Radiology, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
4Department of Surgery, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
5Division of Gastroenterology, Beth Israel Hospital, Albert Einstein University School of Medicine, New York, New York
6Department of Internal Medicine, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
7Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Keywords
Antiviral therapy and survival, hepatitis B,
hepatocellular carcinoma, tumor ablation
Correspondence
Hie-Won Hann, Liver Disease Prevention
Center, Division of Gastroenterology and
Hepatology, Thomas Jefferson University
Hospital, 1025 Walnut Street, Philadelphia,
PA 19107.
Tel: 215-955-5806; Fax: 215-955-0770;
E-mail: hie-won.hann@jefferson.edu
Funding Information
No funding information provided.
Received: 8 October 2013; Revised: 20
November 2013; Accepted: 26 December
2013
Cancer Medicine 2014; 3(2): 390–396
doi: 10.1002/cam4.197
Abstract
The ultimate goal of antiviral therapy for chronic hepatitis B (CHB) is preven-
tion of hepatocellular carcinoma (HCC). Earlier we reported favorable effects of
antiviral therapy on survival of HCC patients following curative tumor ablation
(Int J Cancer online 14 April 2010; doi: 10.1002/ijc.25382). It was the first
observation made in the United States. We now report 12 year follow-up of
this patient group. CHB patients with no prior antiviral therapy with a single
HCC (≤7 cm) were studied. All patients underwent local tumor ablation as
their first option. Patients diagnosed before 1999 received no antiviral treatment
while those diagnosed after 1999 received antiviral treatment. Survival between
the treated and untreated groups was compared. Among 555 HCC patients seen
at our clinic between 1991 and 2013, 25 subjects were eligible. Nine subjects
(all male patients, median age 53 years [46–66]) did not receive antiviral ther-
apy while 16 (14 male patients, median age 56 years [20–73]) received treat-
ment. Between the two groups, there was no difference in their median tumor
size and levels of alpha-fetoprotein and albumin. However, the survival was sig-
nificantly different (P = 0.001): the median survival of the untreated was
16 months (3–36 months) while that of the treated was 80 months (15–
152 months). Fourteen of 16 treated patients are alive to date with two longest
survivors alive for ≥151 months. In conclusion, concomitant antiviral therapy
for CHB patients with HCC reduces and prevents new/recurrent tumor and
improves survival. This novel treatment strategy offers an alternative to liver
transplantation in patients with HBV-associated HCC.
Introduction
The ultimate goal of anti-HBV treatment for patients with
chronic hepatitis B (CHB) is prevention of hepatocellular
carcinoma (HCC) as shown by prospective [1] and retro-
spective [2, 3] studies of a large number of CHB patients
with advanced liver disease.
The same goal can also be applied for prevention of
new and/or recurrent HCC in patients who had already
developed HCC. Since 2005, we in the United States and
researchers in Japan have reported that concomitant an-
tiviral therapy with local tumor ablation reduced the
new/recurrence of HCC in patients whose initial HCC
was successfully ablated [4–8]. We reported our finding
online in 2010 (Hann et al., Int J Cancer published online
14 April 2010; doi: 10.1002/ijc.25382) [8]. Ours was the
first observation made from the patients in the United
States. Studies of large cohorts from Hong Kong in 2011
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[9] and Taiwan in 2012 [10] have further confirmed the
effect of antiviral therapy on recurrence of HCC after
surgery.
Currently, the treatment of choice for patients with
small HCC in the United States is liver transplantation.
However, shortage of organ supply limits this option for a
number of these patients. Here, we present our long-term
follow-up results of patients with a single HCC (<7 cm)
treated with tumor ablation with or without concomitant
antiviral therapy. The sample size is limited but our obser-
vation spans from 1991 to present, May 2013.
Materials and Methods
Patients
From 1991 to 2013, 555 HCC patients referred to our ter-
tiary Liver Disease Prevention Center, Division of Gastro-
enterology and Hepatology. Among this group, 25
presented with a single tumor <7 cm in diameter and had
not received antiviral therapy prior to HCC diagnosis.
The rest of patients with HCC presented with a large,
multifocal tumor(s) or with metastasis.
These eligible 25 patients with a single tumor had CHB
for years but none of them received antiviral drug prior to
HCC diagnosis due to either unavailability of the drug or
other reasons. Nine HCC patients were identified between
1991 and 1999. They did not receive antiviral therapy due
to unavailability of the drug (designated “the untreated”).
From year 2000 to present, 16 patients were eligible for
study. They were started on antiviral therapy immediately
after diagnosis of HCC (designated “the treated”). We have
observed their clinical course for the past 22 years (1991 to
May 2013) with a follow-up magnetic resonance imaging
(MRI) at 1 month following tumor ablation, subsequently
at three monthly intervals and later every 6 months
throughout. Various HCC treatment options including
liver transplantation were presented and discussed. All
patients chose the local tumor ablation as the first option.
Diagnosis of HCC
After referral, the diagnosis of HCC was reconfirmed at
Jefferson by imaging studies including MRI in addition to
alpha-fetoprotein (AFP) or histology (biopsy brought
from outside). Dynamic MRI showing arterial enhance-
ment with washout was used for final diagnosis of HCC
as defined by American Association for Study of Liver
Disease guideline [11–13] and by our institution [14] that
showed arterial enhancement followed by wash out in the
last phase during hepatic arteriography. If MRI evaluation
was confirmative, further needle tumor biopsy was
avoided for fear of needle track seeding.
Treatment of HCC
Before treatment, various therapeutic procedures includ-
ing liver transplantation were discussed with patients. All
patients in this study opted for local tumor ablation as an
initial treatment.
All patients with a single HCC (≤7 cm) lesion under-
went local tumor ablative procedures including surgical
resection, transarterial chemoembolization (TACE), radio-
frequency ablation (RFA), percutaneous ethanol injection
(PCEI), cryoablation, Yttrium90 radioembolization with
glass microspheres, or laparoscopic RFA (Lap-RFA).
Tumor elimination was considered successful when previ-
ously identified contrast enhancement was no longer
identified. Follow-up MRI was obtained 1 month later
and at 3-month intervals subsequently.
Antiviral therapy (only oral nucleos(t)ides
applied)
Regarding antiviral therapy, lamivudine (LAM) was the
only drug available until 2002 when adefovir dipivoxil
(ADV) was approved. More drugs were used when they
became available; Entecavir (ETV) in 2005, telbivudine
(TLV) in 2006, and tenofovir disoproxil fumarate (TDF) in
2008. ADV or TDF was added when patients showed viro-
logic breakthrough (one log increase in HBV DNA level
[copies/mL] after reaching the nadir while on LAM). Fur-
thermore, with the increasing preference of combination
therapy to monotherapy, TDF or ADV was added to LAM
even without virologic breakthrough as time went on. TLV
and ETV were also used as anti-HBV drugs for later arriv-
als. These patients continued on anti-HBV therapy without
interruption following the initial diagnosis of HCC.
HBV DNA quantitation
For HBV DNA levels, a solution hybridization assay (Ab-
bott Laboratories, North Chicago, IL) was used between
2000 and 2002 with a lower limit of detection (LLOD) of
1.6 pg/mL. These values were converted to copies/mL by
determining 283,000 copies/mL, per 1 pg/mL of HBV
DNA. From 2003 onward, HBV DNA was measured by
RT-PCR (polymerase chain reaction) (Quest Diagnostics,
Horsham, PA) with a LLOD of 500 copies/mL. Serial
dilutions were performed for samples exceeding 5.3 log10
copies/mL. Values below this cutoff were assigned a value
of 1 log10 copies/mL. Recently, the cutoff level is
<160 copies/mL by the same laboratories.
Statistical analysis
To examine the difference between the treated and
untreated group in survival and other factors including
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the age, tumor size, serum albumin, platelets, and HBV
DNA level, Mann–Whitney test was used for continuous
variables and Fisher’s exact for categorical variable. Kap-
lan–Meier was used for the survival analysis. The study
was approved by the Institutional Review Board of
Thomas Jefferson University.
Results
Among the 555 patients who presented with HCC at
Liver Disease Prevention Center, Thomas Jefferson Uni-
versity Hospital between 1991 and 2013, all but one were
Asian Americans with CHB with or without cirrhosis.
Of those, 25 with a single HCC ≤7 cm in diameter
were included in the study. They were Asian American
patients and had never received antiviral therapy prior to
diagnosis of HCC.
Nine untreated patients were all men with a median
age of 53 years (48–66 years). Of the 16 anti-HBV treated
patients, 14 were men and two were women with a med-
ian age of 57 years (20–73 years). All were HBsAg posi-
tive and negative for anti-HCV at the time of initial HCC
diagnosis. The majority (7/9 untreated and 13/16 treated)
were negative for HBeAg and positive for anti-HBe.
There were no significant differences between the
untreated and the treated in the following factors: median
tumor size, baseline HBV DNA level, AFP, albumin, and
platelet count as shown in Table 1.
Antiviral therapy
As shown in Table 2, the majority received LAM as the
first-line therapy in early 2000 and later TLV in two
patients. ADV or TDF were later added. With anti-HBV
therapy, HBV DNA became undetectable in all nine
patients at median 8 months (range 3–13 months). Three
patients developed virological breakthrough with LAM at
months 22, 24 and 27, respectively, and were placed on
combination therapy with TDF or ADV. In two patients,
TDF was added to LAM before virological breakthrough.
For those with low baseline HBV DNA, one drug was
started and as long as they remained with undetectable
HBV DNA, the medication was not changed. All patients
on antiviral therapy have maintained undetectable HBV
DNA levels and were followed at three to four monthly
intervals. All patients underwent curative tumor ablation
and the treated group received anti-HBV therapy soon
after the index HCC diagnosis was made. Detailed medi-
cation and tumor ablation are shown in Tables 3 and 4.
Tumor recurrence and survival
Recurrence
As shown in Table 3, all untreated patients developed
recurrent or new tumor(s) following the initial tumor
ablation with progression at 2–12 months in 8/9 patients.
These eight patients died within 17 months. One patient
Table 1. Comparison of the untreated and the treated.
Untreated (9) Treated (16)
P value
(by Mann–
Whitney)
Year of
diagnosis
1991–1999 2000–2010
Age 53 (46–60) 57 (20–73) 0.61
Size of
tumor (cm)
3 (1–6.9) 2.65 (1–7) 0.67
AFP (ng/mL) 484 (3.1–1864) 19.7 (3–14,101) 0.53
Child-pugh 5A, 2B, 2C 14A, 1B, 1C 0.169
(Fisher’s
exact)
HBV DNA 8.4 9 106 copies/mL
(770–1.6 9 107
copies/mL)
2.4 9 105
copies/mL
(500–2.4 9 108
copies/mL)
0.142
Albumin 4.2 (3.1–4.7) 4.2 (3.1–4.9) 0.30
Platelets 126 (62–152) 141 (63–253) 0.12
AFP, alpha-fetoprotein.
Table 2. HBV DNA response on antiviral therapy in the treated
group.
Pts Year Dx
Baseline
HBV DNA
(copies/mL) Anti-HBV therapy
HBV DNA
(-) in months
on anti-HBV
therapy
1 2000 3.40 9 106 LAM + TDF later 3
2 2000 6.70 9 105 LAM + TDF later 8
3 2001 1.10 9 106 LAM + TDF later 5
4 2003 8.90 9 102 LAM + ADV later 10
5 2003 5.00 9 102 LAM + TDF later 6
6 2003 7.60 9 106 LAM + TDF later 9
7 2004 5.00 9 102 LAM 3
8 2004 3.30 9 105 LAM + TDF 3
9 2005 1.10 9 104 LMM + ADV 5
10 2006 1.00 9 107 LAM + TDF 8
11 2007 1.30 9 105 TLV + TDF 3
12 2008 4.40 9 102 LAM + TDF 1
131 2008 2.40 9 108 LAM + ADV 4
14 2009 1.40 9 107 TLV + TDF 7
15 2009 1.20 9 104 TDF 6
16 2010 1.40 9 105 TDF 5
LAM, lamivudine; TDF, tenofovir disoproxil fumarate; ADV, adefovir
dipivoxil; TLV, telbivudine; HCC, hepatocellular carcinoma.
1This patient discontinued antiviral drugs 1 year after HCC ablation.
One year later (off medicine for a year), he returned with recurrent
tumor and HBV DNA 2E + 09 (2 9 109 copies/mL). He died of HCC
at 50 months after diagnosis.
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developed new HCC at 20 months and died of metastasis
at 36 months.
On the other hand, among the 16 who received antivi-
ral therapy, 14 patients are alive and have continued anti-
HBV treatment as shown in Table 4. These 14 received
one or repeated ablative procedures with successful
results. One 73 year-old man (Pt. no. 12) with a single
7 cm HCC received 2x TACE, PCEI (incomplete due to
coughing during procedure) and Lap-RFA for the large
HCC in the Rt lobe. A new small lesion in the Lt lobe
appeared at 13th month and it was chemoembolized with
success. He is alive at 59 months and on antiviral therapy
without evidence of viable tumor. One patient (Pt. no. 4),
with successful PCEI ablation of Rt lobe HCC and con-
comitant antiviral therapy, had remained tumor-free for
7 years. During his trip abroad, he ran out of medicine
for 3 weeks due to unexpected delay of return. On return
home, he immediately restarted antiviral drugs. Three
months later, on a follow-up MRI, a new 6 mm lesion
was detected at different site (Lt lobe) of the liver. During
Table 3. Recurrence of HCC in patients who did not receive antiviral therapy.
Pt
Year
of Dx Age Sex
Tumor size
(cm), site
Child-pugh
class
Initial tumor
ablation
Antiviral
therapy
Recurrence
(months) Retreatment
Survival
(months) Status
1 1991 66 M 2 Rt C TACE None 2 TACE 3 Dead
2 1994 58 M 3 Rt A Resection None 20 Resectionx2 36 Dead
3 1996 46 M 4 Lt A Cryoablation None 5 Cryo, TACE 17 Dead
4 1996 53 M 3 Rt A Cryoablation None 5 TACE, chemo 9 Dead
5 1996 53 M 4 Rt A Resection None 12 TACEx2 16 Dead
6 1997 59 M 1 Rt B PCEI None 2 ChemoRx 6 Dead
7 1999 48 M 2.5 Rt C TACE None 3 TACE multiple 16 Dead
8 1999 60 M 2.5 Lt A TACE, RFA None 9 TACE 17 Dead
9 1999 53 M 6.9 Rt B TACE None 6 Incomplete Ablation,
multiple times
6 Dead
HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PCEI, percutaneous ethanol injection; RFA, radiofrequency ablation.
Table 4. Reduced HCC recurrence in patients on antiviral therapy.
Pts
Year
Dx Age Sex
Tumor
size
(cm)
Child-
pugh
class
Initial tumor
ablation
Anti-HBV
therapy
Recurrence
in months Retreatment
Survival
in months Status
1 2000 57 M 2.5 Rt A RFA LAM + TDF None None 152 Alive
2 2000 64 F 2.5 Rt A RFA LAM + TDF Residual TACE 151 Alive
3 2001 49 M 4.0 Rt A Resection LAM + TDF None None 140 Alive
4 2003 59 M 1.7 Rt A PCEI LAM + ADV None1 None 116 Alive
5 2003 50 M 2.5 Rt B Resection + RFA LAM + TDF None None 116 Alive
6 2003 41 M 2.0 Rt A RFA LAM + TDF None None 116 Alive
7 2004 60 M 3.4 Rt A TACE + RFA LAM None None 104 Alive
8 2004 55 M 4.6 Rt A TACE LAM + TDF 5 9 4 cm at
6 months
Lap-RFA
chemo
15 Dead
9 2005 57 M 3.2 Rt A RFA, resection LAM + ADV None None 94 Alive
10 2006 67 M 1.0 Rt A RFA LAM + TDF None None 88 Alive
11 2007 20 F 2.8 Rt A RFA + TACE TLV + TDF None None 65 Alive
12 2008 73 M 7.0 Rt B TACE x2, PCEI, RFA LAM + TDF Residual None 57 Alive
131 2008 65 M 2.3 Rt A TACE LAM + ADV None None 50 Dead
14 2009 51 M 4.0 Rt A TACE TLV + TDF None None 50 Alive
15 2009 53 M 3.0 Rt A TACEx2 TDF None None 38 Alive
16 2010 66 M 1.4 Rt A TACE TDF None None 26 Alive
HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; LAM, lamivudine; TDF, tenofovir disoproxil fumarate; PCEI, percutaneous ethanol
injection; ADV, adefovir dipivoxil; TACE, transarterial chemoembolization; Lap, laparoscopic; TLV, telbivudine.
1Pt (no. 4) following successful PCEI ablation of Rt lobe HCC remained tumor-free for 7 years. During his trip abroad, he ran out of medicine for
3 weeks. Restarted antiviral drugs. Three months later, on a follow-up visit MRI, a new 6 mm lesion was detected at different site (Lt lobe) of the
liver. At 3-month follow-up, the lesion grew to 1 cm and it was TACE’d. Pt (no. 4) is tumor-free for 4 years since and is on antiviral therapy.
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another 3-month follow-up, the lesion grew to 1 cm and
he underwent TACE. He has remained free of recurrence
for 4 years since and is on antiviral therapy. Of the two
longest survivors who were diagnosed in 2000, one
received RFA once and the other RFA followed by TACE.
Both are alive without recurrence for over 12 years (152
and 151 months, respectively).
Of the treated patients, two died: One 55-year-old man
(Pt. no. 8) developed recurrent tumor at 6 months fol-
lowing initial TACE and died of advanced HCC at
15 months. The other (Pt. no. 13), a 65-year-old man,
after successful tumor ablation and with no recurrence,
lost follow-up 1 year later. After 1 year during which time
he did not receive antiviral therapy, patient returned with
recurrent HCC and increased HBV DNA (2 9 109 cop-
ies/mL). He died of multifocal HCC at 50 months.
Survival
The median survival of the untreated was 16 months
(ranges 3–36 months) and of the treated was 80 months
(15–152 months). The survival difference between the two
groups was significantly different (P = 0.001) (Fig. 1).
Discussion
As summarized extensively by Forner et al. [11], patients
with HBV-HCC, even after successful treatment of the
initial HCC, used to succumb to cancer following multi-
ple recurrences or metastases. Most plausible cause for
this outcome is that the hepatocarcinogen, the virus, con-
tinues to replicate in the liver and thus the carcinogenic
process persists. Following the first introduction of antivi-
ral drug, LAM, it appeared possible that antiviral therapy
could reduce the incidence of HCC attributed to suppres-
sion of the virus [1–3]. Furthermore, in CHB patients
with HCC, Piao et al. [4.] and Kuzuya et al. [5] in a
median follow-up study of 12 months, reported a favor-
able effect of anti-HBV (LAM) therapy in reducing tumor
recurrence and improving survival following curative
resection. Kim et al. [7] observed HCC recurrence rate of
77% in 43 antiviral treated and 92% in 36 untreated
patients after a median follow-up of 12 months. These
authors attributed the longer survival of anti-HBV treated
HCC patients to improvement of liver function with viral
suppression and advocated antiviral therapy. In a study of
40 CHB patients with HCC, Kubo et al. [6] concluded
that high viral load was one of the risk factors for HCC
recurrence following surgical resection. Chan et al. [9]
presented 136 patients who underwent major hepatec-
tomy for the HBV-related HCC by one team of surgeons.
The antiviral-treated group (n = 42) showed overall sur-
vival rate of 88.1%, 79.1% and 71.2% at 1, 3, 5 years,
respectively, while that of antiviral untreated cohort
showed 76.5%, 47.5%, and 43.5% at 1, 3, 5 year, respec-
tively.
Earlier, we reported an 8 year follow-up study of 15
patients with a single HCC (≤4 cm in diameter) [8]. Fol-
lowing successful local tumor ablation, nine patients
received antiviral therapy and six patients did not receive
antiviral therapy due to unavailability. There was a signif-
icant difference in their survival; the median survival of
the untreated and the treated was 12.5 and 60 months,
respectively (P = 0.0001). All treated patients reached to
undetectable HBV DNA within 10 months on antiviral
therapy and maintained negative serum HBV DNA
throughout. Recently, Wu et al. [10] in their study of
Taiwan National Health Insurance data reported the
results of a meta-analysis on the association between the
nucleoside treated group and the untreated group as to
the risk of HCC recurrence. The nucleoside analogues,
LAM, ETV, and TLV, were the antivirals used. The trea-
ted group showed 20.9% of HCC recurrence rate (106/
518) while the untreated cohort presented recurrence rate
of 43.6% (1765/4051).
In this study, we expanded the inclusion criteria to a
single tumor up to ≤7 cm in diameter and were able to
include nine untreated controls and 15 treated. The trea-
ted group received the combination of LAM and TDF,
LAM and ADV, or TLV and TDF. Within 10 months of
antiviral therapy all treated subjects showed undetectable
HBV DNA, and they maintained undetectable HBV DNA
levels throughout with the HBV DNA assayed at six
monthly intervals. Follow-up MRI after local tumor abla-
tion was performed at 1 month and at three monthly
intervals thereafter for the first 3 years and six monthly
subsequently. Patients were followed by the same group
of physicians at the clinic for over 12 years. Patients’
compliance was excellent except one patient (Pt. no. 13)
Figure 1. Survival difference between the anti-HBV treated and
untreated patients.
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who after 1 year following TACE and antiviral therapy
was lost in follow-up for a year. He returned 2 years later
with recurrent HCC with the high HBV DNA level. He
was restarted with antiviral and underwent more TACE
but needed systemic chemotherapy. He died at 50 months
after the index HCC diagnosis.
The carcinogenic process by sustained viremia with
active viral replication has long been considered to be the
result of the viral DNA insertion in or near proto-oncog-
enes, tumor suppressor genes or regulatory element of
cellular DNA or the integration of viral DNA that leads
to the production of the transactivator protein HBxAg
and binding to P53 tumor suppressor genes. It appears
that continuous viral replication is the key risk factor for
recurrence and/or progression of hepatocarcinogenesis. It
is interesting to speculate that even at the precancerous
stage, elimination of the hepatocarcinogen and interrup-
tion of the final trigger may be able to prevent its pro-
gression to cancer. Therefore, successful control of HBV
replication is of utmost importance in prevention of
tumor recurrence and improvement of survival.
Similar observations have been made in hepatitis C
related HCC by other investigators [15–19]. Those who
continued interferon therapy after tumor ablation had
better survival than those who did not receive interferon
therapy. This suggested that control of HCV replication
was an important factor for improved survival of patients
with HCV-related HCC.
Recently, ablative therapies have evolved with the
development of more powerful devices which can deposit
more energy into tumors and create a potentially greater
zone of necrosis. While patients treated later in our clinic
may have benefited from the improvement of available
devices, it is important to consider that in all cases, our
group achieved complete necrosis of the index tumor
based on the follow-up imaging studies.
In this study, status of liver disease defined by Child-
Pugh class was somewhat advanced for the untreated
group (5A, 2B, 2C) than that for the treated group, (14A
and 2B) although there was no significant difference
(P = 0.169). In the untreated group, there were two
patients who were Child-pugh class C and none in the
treated group. Although not different statistically, their
poorer liver function in the untreated may have partly
contributed to their poorer survival. Nonetheless, the
striking survival difference observed is far beyond this
reasoning.
Furthermore, it is not known that while not receiving
chemotherapy, this degree of difference of liver disease
status would affect the development of new/recurrent
HCC.
Our long-term study of over 12 years, albeit small in
numbers, strongly indicates that even after developing
HCC, continuous suppression of viral replication in CHB
patients does reduce and prevent new/recurrent tumor
and improves survival. Patients with a single small HCC,
in addition to the local tumor ablation, should receive
anti-HBV therapy. This novel treatment strategy offers an
alternative to liver transplantation in patients with HBV-
associated HCC.
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